These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22336882)

  • 21. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
    Hall SJ; Klotz L; Pantuck AJ; George DJ; Whitmore JB; Frohlich MW; Sims RB
    J Urol; 2011 Sep; 186(3):877-81. PubMed ID: 21788048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sipuleucel-T (Provenge).
    Urol Nurs; 2012; 32(2):99. PubMed ID: 22690467
    [No Abstract]   [Full Text] [Related]  

  • 25. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
    Bulloch MN; Elayan MM; Renfroe HR
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
    Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
    Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Provenge: revolutionary technology or ethical bust?
    Dickerson JB
    Hum Vaccin; 2011 Apr; 7(4):477-80. PubMed ID: 21451262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    Small EJ; Schellhammer PF; Higano CS; Redfern CH; Nemunaitis JJ; Valone FH; Verjee SS; Jones LA; Hershberg RM
    J Clin Oncol; 2006 Jul; 24(19):3089-94. PubMed ID: 16809734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
    Beer TM; Schellhammer PF; Corman JM; Glodé LM; Hall SJ; Whitmore JB; Frohlich MW; Penson DF
    Urology; 2013 Aug; 82(2):410-5. PubMed ID: 23896100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
    Peppercorn J; Armstrong A; Zaas DW; George D
    Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
    Harris E
    Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P; Higano CS
    Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
    Kibel AS; Inman BA; Pachynski RK; Vu T; Sheikh NA; Petrylak DP
    J Natl Cancer Inst; 2022 Feb; 114(2):310-313. PubMed ID: 33630063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.